###begin article-title 0
Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor and Cognitive Function in Non-Demented Subjects
###end article-title 0
###begin p 1
Conceived and designed the experiments: GL ERP SPM PC IS CEY LB MAR DG TM. Performed the experiments: IS CEY LB. Analyzed the data: GL SPM PC. Contributed reagents/materials/analysis tools: ERP CEY MAR DG TM. Wrote the paper: GL ERP SPM PC IS CEY LB MAR DG TM.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Brain-derived neurotrophic factor (BDNF) is an activity-dependent secreted protein that is critical to organization of neuronal networks and synaptic plasticity, especially in the hippocampus. We tested hypothesis that reduced CSF BDNF is associated with age-related cognitive decline.
###end p 3
###begin title 4
Methodology/Principal Findings, and Conclusions/Significance
###end title 4
###begin p 5
###xml 32 34 29 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">42</sub>
###xml 200 216 197 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Apolipoprotein E</italic>
###xml 221 225 218 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BDNF</italic>
###xml 230 236 227 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs6265</italic>
###xml 613 615 607 609 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">42</sub>
###xml 635 639 629 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 644 648 638 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BDNF</italic>
###xml 110 118 <span type="species:ncbi:9606">patients</span>
###xml 159 167 <span type="species:ncbi:9606">patients</span>
###xml 402 410 <span type="species:ncbi:9606">patients</span>
###xml 529 534 <span type="species:ncbi:9606">women</span>
###xml 540 543 <span type="species:ncbi:9606">men</span>
CSF concentration of BDNF, Abeta42 and total tau were measured in 128 cognitively normal adults (Normals), 21 patients with Alzheimer's disease (AD), and nine patients with Mild Cognitive Impairment. Apolipoprotein E and BDNF SNP rs6265 genotype were determined. Neuropsychological tests were performed at baseline for all subjects and at follow-up visits in 50 Normals. CSF BDNF level was lower in AD patients compared to age-matched Normals (p = 0.02). CSF BDNF concentration decreased with age among Normals and was higher in women than men (both p<0.001). After adjusting for age, gender, education, CSF Abeta42 and total tau, and APOE and BDNF genotypes, lower CSF BDNF concentration was associated poorer immediate and delayed recall at baseline (both p<0.05) and in follow up of approximately 3 years duration (both p<0.01).
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
Reduced CSF BDNF was associated with age-related cognitive decline, suggesting a potential mechanism that may contribute in part to cognitive decline in older individuals.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 531 534 531 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Hariri1">[1]</xref>
###xml 536 539 536 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Egan1">[2]</xref>
###xml 653 661 653 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val66Met</italic>
###xml 665 673 665 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Met-BDNF</italic>
###xml 775 778 775 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Miyajima1">[3]</xref>
###xml 848 851 848 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Hariri1">[1]</xref>
###xml 853 856 853 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Egan1">[2]</xref>
###xml 910 913 910 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Egan1">[2]</xref>
###xml 1022 1025 1022 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Miyajima1">[3]</xref>
###xml 1027 1030 1027 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Bueller1">[4]</xref>
###xml 1141 1149 1141 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Met-BDNF</italic>
###xml 1241 1249 1241 1249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Met-BDNF</italic>
###xml 1262 1270 1262 1270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val-BDNF</italic>
###xml 1287 1295 1287 1295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Met-BDNF</italic>
###xml 1365 1368 1365 1368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Egan1">[2]</xref>
###xml 524 530 <span type="species:ncbi:9606">humans</span>
###xml 577 582 <span type="species:ncbi:9606">human</span>
###xml 799 807 <span type="species:ncbi:9606">patients</span>
Age-related cognitive decline is a complex convergent phenotype that likely derives in part from brain senescence and in part from prodromal dementing illnesses, most commonly Alzheimer's disease (AD). Brain-derived neurotrophic factor (BDNF) is an activity-dependent secreted protein that, along with its receptors, is expressed widely in the central nervous system and is critical to organization of neuronal networks and synaptic plasticity, especially in the hippocampus, in a variety of animal models and apparently in humans [1], [2]. Although controversy remains, these human data derive mostly from investigations of an allelic variant of BDNF (Val66Met or Met-BDNF), inheritance of which has been associated with poorer cognitive performance in healthy older adults [3], impaired memory in patients with schizophrenia and healthy controls [1], [2], abnormal hippocampal activation as assessed by fMRI [2], and an approximately 4% to 11% smaller hippocampal volume as determined by MRI in healthy adult volunteers [3], [4]. The mechanisms that underlie these associations of functional and structural differences with inheritance of Met-BDNF are not clear; however, one study has shown diminished depolarization-induced secretion of Met-BDNF compared to Val-BDNF, and failure of Met-BDNF to localize to secretory granules or synapses in transfected neurons [2]. Together, these findings have led to the hypothesis that reduced BDNF secretion is one mechanism of age-related cognitive decline. We are unaware of any published study that has yet tested this hypothesis.
###end p 9
###begin title 10
Methods
###end title 10
###begin p 11
###xml 392 395 392 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Petersen1">[5]</xref>
###xml 412 415 412 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-McKhann1">[6]</xref>
###xml 527 530 527 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Zhang1">[7]</xref>
All procedures were approved by the institutional review boards of the University of Washington; all subjects were recruited from University of Washington Alzheimer's Disease Research Center and provided written informed consent. Subjects underwent detailed clinical and laboratory evaluation and were classified as no cognitive impairment (Normals), amnestic mild cognitive impairment (MCI) [5], or probable AD [6]. Inclusion and exclusion criteria, method of CSF collection, and analysis were exactly as previously described [7].
###end p 11
###begin p 12
###xml 46 48 43 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">42</sub>
###xml 89 92 86 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Zhang1">[7]</xref>
###xml 94 98 91 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 154 157 151 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Hixson1">[8]</xref>
###xml 159 163 156 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BDNF</italic>
###xml 168 174 165 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs6265</italic>
###xml 260 263 257 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Bekris1">[9]</xref>
CSF concentration of BDNF, total tau and Abeta42 was measured using an X-MAP-based assay [7]. APOE genotype was determined by a restriction digest method [8]. BDNF SNP rs6265 was genotyped using TaqMan allelic discrimination detection, as previously described [9].
###end p 12
###begin p 13
###xml 87 91 87 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Newcomer1">[10]</xref>
###xml 93 97 93 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Craft1">[11]</xref>
###xml 179 183 179 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Wechsler1">[12]</xref>
###xml 330 334 330 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Gomez1">[13]</xref>
###xml 577 581 577 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Reitan1">[14]</xref>
Neuropsychological tests included: (i) Paragraph Recall - a test of declarative memory [10], [11]. Paragraphs were modeled after the Logical Memory subtests I and II of the WMS-R [12]. Total score for immediate recall and delayed recall (each with possible range 0-25) were used. (ii) Category Fluency - a test of semantic memory [13]. Total number of unique animals named in 60 seconds was used. (iii) Trail Making Test, Parts A and B - test of ability to adapt to shifting task demands. Time taken to complete Part B (upper bound of 300 sec), a measure of executive function [14], was used.
###end p 13
###begin p 14
###xml 51 59 51 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post hoc</italic>
###xml 837 841 837 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Milliken1">[15]</xref>
###xml 1015 1019 1015 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Corporation1">[16]</xref>
###xml 1040 1044 1040 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Team1">[17]</xref>
One-way analysis of variance (ANOVA) was used with post hoc Bonferroni multiple pair-wise comparisons for continuous variables and Fisher's exact test for categorical variables to assess differences between diagnostic and genetic groups. Linear regression models were used for associations of demographic characteristics with CSF BDNF concentration, and cross-sectional relationships between CSF BDNF concentration and coincident cognitive test performance. Raw scores were used for each test except log-transformed times for Trails B to remove skewness. We used two-stage regression (least squares slope for each test in each individual over time, then weighted regression model with slope as response variable) to assess association of baseline CSF BDNF concentration with subsequent longitudinal changes of cognitive test performance [15]. Weights were based on subjects having different numbers of follow-up visits at different times after baseline. Statistical analyses were performed using S-PLUS version 8.0 [16] and R version 2.7.1 [17].
###end p 14
###begin title 15
Results
###end title 15
###begin title 16
Age-matched Normals, MCI, and AD
###end title 16
###begin p 17
###xml 0 7 0 7 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005424-t001"><bold>Table 1</bold></xref>
###xml 382 390 380 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post-hoc</italic>
###xml 530 538 528 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Met-BDNF</italic>
###xml 549 567 547 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G/G vs. G/A or A/A</italic>
###xml 725 733 723 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Met-BDNF</italic>
###xml 743 746 741 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G/G</italic>
###xml 770 773 766 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G/A</italic>
###xml 800 803 794 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A/A</italic>
###xml 109 117 <span type="species:ncbi:9606">patients</span>
###xml 322 330 <span type="species:ncbi:9606">patients</span>
###xml 451 459 <span type="species:ncbi:9606">patients</span>
Table 1 presents demographics and baseline CSF BDNF levels in 128 normal controls (Normals), 9 MCI and 21 AD patients. To compare measures between these three groups after adjusting for age, a subset of the Normals (n = 76) age>/=50 years (Older Normals, ON) was used as a comparison group. CSF BDNF level was lower in AD patients compared to ON with a mean difference of 25 pg/ml (post-hoc Bonferroni test, p = 0.02). CSF BDNF level for the nine MCI patients was not different from either group (both p>0.05). The frequencies of Met-BDNF genotype (G/G vs. G/A or A/A) were not different between ON, MCI, and AD subjects (Fisher's Exact Test p = 0.36). Moreover, CSF BDNF concentration in AD subjects was not different among Met-BDNF genotype G/G (70%, 217+/-38 pg/ml), G/A (25%, 214+/-39 pg/ml), or A/A (5%, 213 pg/ml, n = 1) (F = 0.02, df = 2, p = 0.99).
###end p 17
###begin title 18
Subject characteristics and CSF BDNF levels at baseline.
###end title 18
###begin p 19
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ON</bold>
###xml 19 22 19 22 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MCI</bold>
###xml 51 53 51 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AD</bold>
ON: Older Normals; MCI: Mild Cognitive Impairment; AD: Alzheimer disease; MMSE: Mini-Mental State Exam.
###end p 19
###begin p 20
Missing Values. Race - 1 (AD). APOE - 2 (one ON, one AD). BDNF Genotype - 4 (two ON, one MCI, one AD). Education - 1 (AD).
###end p 20
###begin p 21
p-value based on one-way ANOVA for continuous variables and Fisher's exact test for categorical variables. No comparison between groups was performed for MMSE since this test is used for diagnosis.
###end p 21
###begin title 22
CSF BDNF concentration in all cognitively normal subjects
###end title 22
###begin p 23
###xml 96 98 93 95 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">42</sub>
###xml 164 171 161 168 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 164 171 161 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005424-t001"><bold>Table 1</bold></xref>
###xml 221 227 218 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs6265</italic>
###xml 249 252 246 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G/G</italic>
###xml 276 279 271 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G/A</italic>
###xml 306 309 299 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A/A</italic>
Our focus was on 128 cognitively normal volunteers (Normals) in whom we measured CSF BDNF, Abeta42, and total tau, and who underwent neuropsychological evaluation (Table 1). CSF BDNF concentration was not different among rs6265 genotype in Normals: G/G (60%, 242+/-37 pg/ml), G/A (36%, 253+/-26 pg/ml), or A/A (5%, 251+/-28 pg/ml) (F = 1.52, df = 2, p = 0.22).
###end p 23
###begin p 24
###xml 104 112 104 112 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1</bold>
###xml 104 112 104 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005424-g001"><bold>Figure 1</bold></xref>
###xml 224 228 224 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 250 278 244 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Met-BDNF (G/G vs G/A or A/A)</italic>
###xml 407 420 401 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE &#949;4</italic>
###xml 443 451 431 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Met-BDNF</italic>
###xml 541 554 529 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE &#949;4</italic>
###xml 566 574 548 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Met-BDNF</italic>
###xml 836 838 815 817 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">42</sub>
###xml 74 79 <span type="species:ncbi:9606">women</span>
###xml 85 88 <span type="species:ncbi:9606">men</span>
CSF BDNF concentration decreased with age among Normals and was higher in women than men (both p<0.001; Figure 1). In a multivariate linear regression with CSF BDNF as the dependent variable and age, gender, presence of the APOE epsilon4 allele, and Met-BDNF (G/G vs G/A or A/A) as independent predictors, both age and gender were significantly associated with CSF BDNF level (p<0.001). Neither presence of APOE epsilon4 allele (p = 0.33) nor Met-BDNF (p = 0.09) was related to CSF BDNF levels. In addition, there was no interaction between APOE epsilon4 allele and Met-BDNF genotype (p = 0.25), nor between age and gender (p = 0.45). Removing the three lowest values of BDNF for males did not change the results. Finally, after adjusting for age and gender, CSF BDNF levels were related inversely (slope = -0.03) to CSF levels of Abeta42 (p = 0.05) but not to CSF total tau (p = 0.34).
###end p 24
###begin title 25
Cross-sectional relationships between age and CSF BDNF concentration by gender.
###end title 25
###begin title 26
Association between CSF BDNF concentration, memory, and cognitive ability in cognitively normal subjects at baseline
###end title 26
###begin p 27
###xml 83 90 83 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 83 90 83 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005424-t001"><bold>Table 1</bold></xref>
###xml 93 100 93 100 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 93 100 93 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005424-t002"><bold>Table 2</bold></xref>
###xml 388 390 385 387 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">42</sub>
###xml 444 448 441 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Li1">[18]</xref>
###xml 450 454 447 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Fagan1">[19]</xref>
###xml 530 543 527 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE &#949;4</italic>
###xml 548 556 539 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Met-BDNF</italic>
###xml 718 720 706 708 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">42</sub>
###xml 783 796 771 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE &#949;4</italic>
###xml 801 809 783 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Met-BDNF</italic>
Most (n = 121) Normals underwent extensive neuropsychological testing at baseline (Table 1). Table 2 shows the regression coefficients and p-values associated with baseline CSF BDNF levels for each cognitive test in multivariate regression models after adjusting for age, gender, and years of education (Model 1); adjusting for the previous variables as well as concentration of CSF Abeta42 and total tau (biomarkers of latent and prodromal AD [18], [19], Model 2); and adjusting for the previous variables as well as presence of APOE epsilon4 and Met-BDNF (Model 3). There was an association between higher CSF BDNF concentrations and better performance on Paragraph Recall - Delayed that was independent of CSF Abeta42 and total tau concentrations (Model 2) as well as presence of APOE epsilon4 and Met-BDNF (Model 3); correlation with the Paragraph Recall - Immediate was significant when all predictor variables were in the model (Model 3). An association between lower CSF BDNF and poor performance on Trail Making Test Part B also was observed. There was no significant correlation between CSF BDNF concentration and performance on the Category Fluency test.
###end p 27
###begin title 28
Relationships between baseline CSF BDNF concentration with cross-sectional and longitudinal cognitive performance.
###end title 28
###begin p 29
###xml 73 91 73 91 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Models 1, 2, and 3</bold>
###xml 347 349 344 346 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">42</sub>
###xml 402 414 399 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE &#949;</italic>
###xml 417 425 408 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#949;4</italic>
###xml 431 439 416 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#949;4</italic>
###xml 446 454 425 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Met-BDNF</italic>
###xml 465 468 444 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G/G</italic>
###xml 473 476 452 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G/A</italic>
###xml 480 483 459 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A/A</italic>
###xml 528 534 507 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs6265</italic>
###xml 546 563 525 542 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Models 4, 5 and 6</bold>
###xml 848 850 824 826 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">42</sub>
###xml 903 915 879 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE &#949;</italic>
###xml 918 925 888 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#949;</italic>
###xml 932 939 896 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#949;</italic>
###xml 947 955 905 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Met-BDNF</italic>
###xml 966 969 924 927 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G/G</italic>
###xml 974 977 932 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G/A</italic>
###xml 981 984 939 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A/A</italic>
Data are: linear regression model coefficient (SE) per10 pg/ml; p-value. Models 1, 2, and 3: Cross-sectional relationships between baseline CSF BDNF concentration and coincident cognitive test scores in 121 Normals with baseline neuropsychological testing. Model 1: adjusted for age, gender, and years of education. Model 2: Model 1 plus CSF Abeta42 and total tau concentrations. Model 3: Model 2 plus APOE epsilon4 (epsilon4- vs. epsilon4+) and Met-BDNF genotype (G/G vs. G/A or A/A) (n = 119 because of two missing values for rs6265 genotype). Models 4, 5 and 6: longitudinal relationships between baseline CSF BDNF concentration and subsequent annual change in cognitive test scores for 50 Normals with follow-up evaluation. Model 4: adjusted for age, gender, years of education, and baseline test score. Model 5: Model 4 plus baseline CSF Abeta42 and total tau concentrations. Model 6: Model 5 plus APOE epsilon4 (epsilon4- vs. epsilon4+) and Met-BDNF genotype (G/G vs. G/A or A/A).
###end p 29
###begin title 30
Association between baseline CSF BDNF concentration and longitudinal changes in cognitive performance
###end title 30
###begin p 31
###xml 236 243 228 235 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 236 243 228 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005424-t001"><bold>Table 1</bold></xref>
###xml 246 254 238 246 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 246 254 238 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005424-g002"><bold>Figure 2</bold></xref>
###xml 751 753 740 742 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">42</sub>
###xml 1003 1016 992 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE &#949;4</italic>
###xml 1021 1029 1004 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Met-BDNF</italic>
###xml 1188 1196 1171 1179 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 1188 1196 1171 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005424-g002"><bold>Figure 2</bold></xref>
###xml 18 23 <span type="species:ncbi:9606">women</span>
Fifty Normals (27 women), aged 40-100 years (mean+/-SD = 71.5+/-8.9) had at least one clinical follow-up visit (mean+/-SD 4.0+/-1.1, Range = 2-6) with an average length of follow-up of 3.3 years (SD = 1.2 years, Range = 0.7-5.8 years) (Table 1). Figure 2 shows unadjusted annual changes in cognitive test scores versus baseline CSF BDNF concentration. After adjusting for age, gender, years of education, and baseline test score, lower values of baseline BDNF concentration were significantly associated with greater annual decline in Immediate and Delayed Recall scores on the Paragraph Recall test, and a greater annual decline in the Category Fluency test (Model 4). These relationships were unchanged after further adjusting for baseline CSF Abeta42 and total tau concentrations (Model 5), suggesting that prediction by baseline CSF BDNF concentration for subsequent cognitive changes is independent of preclinical AD. These relationships also were unchanged after further adjusting for presence of APOE epsilon4 and Met-BDNF (Model 6). All results were unaffected by removing the subject who had the largest annual decline for Immediate Recall, Delayed Recall, and Category Fluency (Figure 2).
###end p 31
###begin title 32
Annual change in cognitive test scores versus baseline CSF BDNF concentration.
###end title 32
###begin title 33
Relationship between BDNF genotype and cognitive performance in the Normals
###end title 33
###begin p 34
###xml 209 217 209 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Met-BDNF</italic>
###xml 228 246 228 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G/G vs. G/A or A/A</italic>
###xml 461 469 461 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Met-BDNF</italic>
Among all Normals (n = 119; 2 missing values for genotype), baseline performance on each of the four cognitive tests (Immediate and Delayed Recall, Category Fluency, and Trail Making Part B) did not differ by Met-BDNF genotype (G/G vs. G/A or A/A, all p>0.05), even after adjusting for age, gender and education in the multiple regression model (all p>0.05). Similarly, the longitudinal changes in these cognitive performances (n = 50) were not associated with Met-BDNF genotype (all p>0.05).
###end p 34
###begin title 35
Discussion
###end title 35
###begin p 36
###xml 190 198 190 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Met-BDNF</italic>
###xml 206 219 206 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE &#949;4</italic>
###xml 102 107 <span type="species:ncbi:9606">human</span>
###xml 233 238 <span type="species:ncbi:9606">Women</span>
###xml 287 290 <span type="species:ncbi:9606">men</span>
We made three novel observations in cognitively normal individuals. (i) CSF BDNF decreased across the human life-span in the absence of dementia or MCI and was independent of inheritance of Met-BDNF or the APOE epsilon4 allele. (ii) Women had higher average CSF BDNF concentrations than men. (iii) Lower CSF BDNF concentration was associated strongly with poorer memory and less so with diminished executive function; importantly, these associations were independent of CSF biomarkers of preclinical AD, suggesting that the mechanisms that contribute to early AD and to age-related decline in CSF BDNF might be independent. We must acknowledge that this study has a relatively small sample size and short duration of follow-up and further studies are needed to validate our results.
###end p 36
###begin p 37
###xml 217 220 217 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Zhang1">[7]</xref>
###xml 222 226 222 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Nagatsu1">[20]</xref>
###xml 250 253 250 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Zhang1">[7]</xref>
###xml 255 259 255 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Zhang2">[21]</xref>
###xml 261 265 261 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Blasko1">[22]</xref>
###xml 421 425 421 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Laske1">[23]</xref>
###xml 532 536 532 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Laske2">[24]</xref>
###xml 174 182 <span type="species:ncbi:9606">patients</span>
###xml 233 241 <span type="species:ncbi:9606">patients</span>
###xml 343 351 <span type="species:ncbi:9606">patients</span>
While ours is the first study of which we are aware to investigate age-related changes in CSF BDNF, other studies have investigated disease-associated changes in CSF BDNF in patients with idiopathic Parkinson disease [7], [20] or in patients with AD [7], [21], [22]. We confirmed that CSF BDNF is further reduced beyond age-related decline in patients with probable AD. CSF and serum BDNF concentrations do not correlate [23]; yet, increased and decreased serum BDNF levels are related to early and late stages, respectively, of AD [24].
###end p 37
###begin p 38
###xml 300 304 300 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005424-Sohrabji1">[25]</xref>
###xml 429 435 <span type="species:ncbi:9606">humans</span>
The gender difference in CSF BDNF observed in this study is especially interesting, and we speculate that this may be due to hormonal effects. Animal studies have shown that estrogen receptors colocalize to cells that express BDNF and its receptor trkB, and estrogen regulates the expression of BDNF [25]. The relationship between estrogen levels and BDNF expression and secretion, and their potential effect on the cognition in humans requires further studied.
###end p 38
###begin p 39
###xml 431 439 431 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Met-BDNF</italic>
###xml 443 456 443 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE &#949;4</italic>
Our data showed that progressive decline in CSF BDNF concentration was a feature of advancing age independent of preclinical AD or dementia, and was associated strongly with reduced performance in declarative memory tests and less strongly with performance on tests of executive function, perhaps a reflection of the special role of BDNF in hippocampal function. Age-related reduction in CSF BDNF was independent of inheritance of Met-BDNF or APOE epsilon4. Further reduction in CSF BDNF occurred in AD. Our data suggest that reduced secretion of BDNF in the central nervous system is one mechanism that may contribute to age-related cognitive decline.
###end p 39
###begin title 40
References
###end title 40
###begin article-title 41
###xml 64 69 <span type="species:ncbi:9606">human</span>
Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance.
###end article-title 41
###begin article-title 42
###xml 80 85 <span type="species:ncbi:9606">human</span>
The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function.
###end article-title 42
###begin article-title 43
Brain-derived neurotrophic factor polymorphism Val66Met influences cognitive abilities in the elderly.
###end article-title 43
###begin article-title 44
BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects.
###end article-title 44
###begin article-title 45
Mild cognitive impairment: clinical characterization and outcome.
###end article-title 45
###begin article-title 46
###xml 128 133 <span type="species:ncbi:9606">Human</span>
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.
###end article-title 46
###begin article-title 47
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases.
###end article-title 47
###begin article-title 48
###xml 25 30 <span type="species:ncbi:9606">human</span>
Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.
###end article-title 48
###begin article-title 49
Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels.
###end article-title 49
###begin article-title 50
###xml 84 90 <span type="species:ncbi:9606">humans</span>
Dose-dependent cortisol-induced increases in plasma leptin concentration in healthy humans.
###end article-title 50
###begin article-title 51
Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study.
###end article-title 51
###begin article-title 52
Using verbal fluency to detect very mild dementia of the Alzheimer type.
###end article-title 52
###begin article-title 53
Mixed effect models of longitudinal Alzheimer's disease data: a cautionary note.
###end article-title 53
###begin article-title 54
CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.
###end article-title 54
###begin article-title 55
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
###end article-title 55
###begin article-title 56
Changes in cytokines and neurotrophins in Parkinson's disease.
###end article-title 56
###begin article-title 57
###xml 52 60 <span type="species:ncbi:9606">patients</span>
Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease.
###end article-title 57
###begin article-title 58
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias.
###end article-title 58
###begin article-title 59
BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls.
###end article-title 59
###begin article-title 60
Stage-dependent BDNF serum concentrations in Alzheimer's disease.
###end article-title 60
###begin article-title 61
Estrogen-BDNF interactions: implications for neurodegenerative diseases.
###end article-title 61
###begin p 62
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 62
###begin p 63
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: National Institution on Aging: P50-AG005136, AG023185 and AG05136; the Nancy and Buster Alvord Endowment; and an anonymous foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 63

